PMID- 29951065
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 9
DP  - 2018
TI  - Monocyte-Derived Dendritic Cells Differentiated in the Presence of Lenalidomide 
      Display a Semi-Mature Phenotype, Enhanced Phagocytic Capacity, and Th1 
      Polarization Capability.
PG  - 1328
LID - 10.3389/fimmu.2018.01328 [doi]
LID - 1328
AB  - Lenalidomide is an analog of thalidomide, with potent anticancer activity 
      demonstrated in several hematological malignancies. It has immunomodulatory 
      properties, being able to enhance the activation of different types of immune 
      cells, which results in antitumor activities. Dendritic cells (DCs) are pivotal 
      in the immune response, and different immunotherapeutic approaches targeting 
      these cells are being developed. Since little is known about the effect of 
      lenalidomide on DCs, the goal of the present work was to investigate the 
      phenotype and function of human monocyte-derived DCs differentiated in the 
      presence of lenalidomide (L-DCs). Our results showed that L-DCs display a unique 
      phenotype, with increased cell surface expression of some maturation markers such 
      as CD1d, CD83, CD86, and HLA-DR. This phenotype correlates with a lower 
      expression of the E3 ubiquitin-ligase MARCH-I in L-DCs, upregulating the cell 
      surface expression of CD86 and HLA-DR. In addition, immature L-DCs express higher 
      amounts of DC-SIGN on the cell surface than control immature DCs. After LPS 
      stimulation, production of IL-6 and TNF-alpha was severely decreased, whereas IL-12 
      and IL-10 secretion was dramatically upregulated in L-DCs, compared to that in 
      the controls. Functionally, L-DCs are more effectively recognized by NKT cells in 
      cytotoxicity experiments. Furthermore, L-DCs display higher opsonin-independent 
      antigen uptake capability than control DCs. Mixed lymphocyte reaction experiments 
      showed that L-DCs could stimulate naive CD4 T-cells, polarizing them toward a 
      predominant Th1 phenotype. In summary, DCs derived from monocytes in the presence 
      of lenalidomide present a semi-mature phenotype, increased phagocytic capacity, 
      reduced production of proinflammatory cytokines, and the ability to polarize 
      T-cells toward predominant Th1-type responses; these are qualities that might be 
      useful in the development of new immunotherapeutic treatments.
FAU - Lopez-Relano, Juan
AU  - Lopez-Relano J
AD  - Departamento de Inmunologia, Facultad de Medicina, Universidad Complutense, 
      Madrid, Spain.
AD  - 12 de Octubre Health Research Institute (imas12), Madrid, Spain.
FAU - Martin-Adrados, Beatriz
AU  - Martin-Adrados B
AD  - Departamento de Inmunologia, Facultad de Medicina, Universidad Complutense, 
      Madrid, Spain.
AD  - 12 de Octubre Health Research Institute (imas12), Madrid, Spain.
FAU - Real-Arevalo, Irene
AU  - Real-Arevalo I
AD  - Departamento de Inmunologia, Facultad de Medicina, Universidad Complutense, 
      Madrid, Spain.
AD  - 12 de Octubre Health Research Institute (imas12), Madrid, Spain.
FAU - Lozano-Bartolome, Javier
AU  - Lozano-Bartolome J
AD  - Departamento de Inmunologia, Facultad de Medicina, Universidad Complutense, 
      Madrid, Spain.
AD  - 12 de Octubre Health Research Institute (imas12), Madrid, Spain.
FAU - Abos, Beatriz
AU  - Abos B
AD  - Departamento de Inmunologia, Facultad de Medicina, Universidad Complutense, 
      Madrid, Spain.
AD  - 12 de Octubre Health Research Institute (imas12), Madrid, Spain.
FAU - Sanchez-Ramon, Silvia
AU  - Sanchez-Ramon S
AD  - Departamento de Inmunologia, Hospital Clinico San Carlos, Madrid, Spain.
FAU - Alonso, Barbara
AU  - Alonso B
AD  - Centro de Investigaciones Biologicas, Madrid, Spain.
FAU - Gomez Del Moral, Manuel
AU  - Gomez Del Moral M
AD  - 12 de Octubre Health Research Institute (imas12), Madrid, Spain.
AD  - Departamento de Biologia Celular, Facultad de Medicina, Universidad Complutense, 
      Madrid, Spain.
FAU - Martinez-Naves, Eduardo
AU  - Martinez-Naves E
AD  - Departamento de Inmunologia, Facultad de Medicina, Universidad Complutense, 
      Madrid, Spain.
AD  - 12 de Octubre Health Research Institute (imas12), Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20180613
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
PMC - PMC6008535
OTO - NOTNLM
OT  - NKT cell
OT  - T-cells
OT  - antigen presentation
OT  - cytokines
OT  - dendritic cells
OT  - lenalidomide
OT  - phagocytosis
EDAT- 2018/06/29 06:00
MHDA- 2018/06/29 06:01
PMCR- 2018/01/01
CRDT- 2018/06/29 06:00
PHST- 2017/11/08 00:00 [received]
PHST- 2018/05/28 00:00 [accepted]
PHST- 2018/06/29 06:00 [entrez]
PHST- 2018/06/29 06:00 [pubmed]
PHST- 2018/06/29 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2018.01328 [doi]
PST - epublish
SO  - Front Immunol. 2018 Jun 13;9:1328. doi: 10.3389/fimmu.2018.01328. eCollection 
      2018.